STAT+: MASH drugs reach a meaningful tipping point for patients and investors

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Drugs that treat the liver disease known as MASH are enjoying a moment of bliss that is well deserved, long in the making, and shouldn’t be fleeting. 

First, Madrigal Pharmaceuticals has been executing a nearly flawless commercial launch of Rezdriffa, with sales already topping $400 million on an annualized basis, less than a year since approval. Then on Monday, Akero Therapeutics reported outstanding results from a study of its drug efruxifermin that demonstrated a statistically significant reversal of cirrhosis in patients with severe MASH.

Continue to STAT+ to read the full story…